MiNK Therapeutics increased investment in its iNKT platform led to a higher net loss in Q3 2025. The company highlighted durable responses from its lead therapy agenT-797 and secured non-dilutive funding for a new GvHD trial, while extending its cash runway through 2026.

MiNK Therapeutics reported a net loss of $4.2 million for Q2 2025, or $1.06 per share, compared to a net loss of $2.7 million, or $0.73 per share, for Q2 2024. The company ended the quarter with $1.6 million in cash and cash equivalents, with subsequent equity sales raising an additional $13 million, extending its cash runway beyond mid-2026.

MiNK reported no revenue for the quarter but significantly reduced its cash burn and net loss year-over-year, while advancing its clinical programs in solid tumors and immune-mediated diseases. The company ended the quarter with $3.2 million in cash and is pursuing strategic partnerships and non-dilutive funding.

In Q4 2024, MiNK Therapeutics reported $0 in revenue, reflecting its clinical-stage development status. The company recorded operating expenses of $2.2 million, resulting in a net loss of $2.5 million. Cash used in operations during the quarter was $1.7 million, and the company ended the quarter with $4.6 million in cash and cash equivalents.

MiNK Therapeutics reported a net loss of $1.8 million, or $0.05 per share, for the third quarter of 2024. The company ended the quarter with a cash balance of $6.3 million.

MiNK Therapeutics reported its second quarter 2024 results, highlighting the advancement of its iNKT programs, particularly agenT-797 in a Phase 2 study for second-line gastric cancer, and the fast-tracking of IND-enabling activities for MiNK-215. The company's cash balance at the end of the quarter was $9.3 million, with a net loss of $2.7 million, or $0.07 per share.

MiNK Therapeutics reported a net loss of $3.8 million, or $0.11 per share, for the first quarter of 2024. The company's cash balance at the end of the quarter was $5.8 million and cash used in operations was $2.5 million.

MiNK Therapeutics reported its Q4 and full-year 2023 financial results, highlighting the progression of its lead program, agenT-797, into a Phase 2 study in gastroesophageal cancers. The company ended the year with a cash balance of $3.4 million and reported a net loss for the year of $22.5 million, or $0.65 per share.

MiNK Therapeutics reported its Q3 2023 financial results, highlighting advancements in its iNKT cell platform, progress in engineered programs, and strides in internal cGMP manufacturing. The company ended the quarter with a cash balance of $6.4 million. AgenT-797 has demonstrated promising results in patients with late-stage metastatic cancer.

MiNK Therapeutics reported its second quarter 2023 results, highlighting clinical progress with agenT-797 and the planned launch of a randomized Phase 2 trial in 2L gastric cancer. The company ended the quarter with a cash balance of $10.6 million.

MiNK Therapeutics reported its Q1 2023 financial results, with a net loss of $5.7 million, or $0.17 per share. The company ended the quarter with a cash balance of $14.9 million. AgenT-797 has shown pioneering data in advanced solid cancers and expansion studies have launched in anti-PD-1 refractory NSCLC and gastric cancer.

MiNK Therapeutics reported a net loss of $7.8 million for the fourth quarter of 2022, with a cash balance of $19.6 million at the end of the quarter.

MiNK Therapeutics reported a net loss of $6.3 million for the third quarter of 2022, with a cash balance of $24.2 million at the end of the quarter. The company highlighted progress in clinical programs, next-generation pipeline development, and scaling up internal cGMP manufacturing capabilities.

MiNK Therapeutics reported a net loss of $6.1 million for the second quarter of 2022, with a cash balance of $29.8 million at the end of the quarter.

MiNK Therapeutics reported a net loss of $7.8 million for Q1 2022, which includes non-cash expenses of $813,000. The company's cash balance at the end of the quarter was $34.7 million.